Structural Heart Disease

Drawing of the heart that shows areas affected by structural heart defects

Structural Heart Disease Management

Transcatheter and surgical solutions

More than 71,000 children in the U.S. and European Union combined are born with structural heart defects each year.1,2 In addition, many adults worldwide battle conditions such as valvular disease and aortic stenosis, the narrowing of the aortic valve. In fact, aortic stenosis is the world’s most common noncongenital valve disease.3 


Abbott offers surgical and transcatheter options for treating structural heart disease. We are focused on improving the lives of patients and offering physicians like you products designed for ease of use and that have proven clinical outcomes.4,5


Drawing of Portico™ Transcatheter Aortic Valve implantated in the native aortic heart valve

Transcatheter Valve Replacement Portfolio

Transcatheter aortic valve implantation (TAVI) or transcatheter aortic valve replacement (TAVR) is an innovative and life-saving treatment option for patients suffering from severe aortic stenosis who cannot undergo open-heart surgery or as an alternative to heart surgery. We offer a catheter-based heart-valve replacement solution designed to deliver exceptional hemodynamics (low gradients) and performance, as well as a market-leading low-profile introducer for excellent clinical outcomes.6

Related Portfolios

Learn about our other portfolio solutions to help manage your patients’ structural heart disease.

Surgical Heart Valve Replacement Portfolio

We are advancing surgical replacement technologies with our mechanical and tissue stented valves. Designed to mimic the function of a natural, healthy heart valve, our valves deliver superior hemodynamics and durability.

Structural Heart Occlusion Portfolio

Our portfolio of minimally invasive, catheter-based structural heart occluders is built on proven AMPLATZER™ technology and designed to treat congenital heart defects. Our occluders feature flexible designs engineered for complete closure.

Celebrating Four Decades of Valve Innovation

As pioneers in heart valve technology, St. Jude Medical is an experienced mechanical valve company in the world with more than two million mechanical valves implanted worldwide to date. We offer catheter-based and surgical solutions—including market-leading mechanical and tissue stented heart valves designed for exceptional hemodynamics, durability and ease of implantation.

It’s part of the excitement of medicine to me. It’s bringing something new to the field.
—Dr. Robert Emery, Cardiovascular and Thoracic Surgeon


Watch this video to learn more about our innovations in heart valve technology.

Valvular Disease: The Next Cardiac Epidemic

According to an article in Heart, an international peer-reviewed journal for health professionals and researchers in all areas of cardiology, the prevalence of valvular heart disease is growing as life expectancy increases.3

Population statistics worldwide project an imminent increase in the elderly population—in the U.K., for example, there will be an estimated 4 million people aged between 75 and 84 by 2018, and the population beyond the age of 85 is set to double by 2028.7

Read the article.

Market-leading AMPLATZER™ structural heart occluders for transcatheter closure of heart defects

Industry-Leading Structural Heart Occluders

At St. Jude Medical, we invest in studies that demonstrate the safety, performance and cost-effectiveness of our transformative therapies. Backed by more than 17 years of clinical experience, our AMPLATZER™ technologies define a market-leading standard of care for transcatheter closure of heart defects.4,8,9

AMPLATZER™ Amulet™ Left Atrial Appendage Occluder AMPLATZER™ Amulet™ Left Atrial Appendage Occluder

We have designed our AMPLATZER™ Amulet™ left atrial appendage occluder for precise positioning and a complete seal of the LAA at the orifice.

See the evidence


†Caution: investigational device (exclusively for clinical investigation) in select international markets. This therapy is not approved by the FDA for use in the United States. Limited by Federal (or United States) law to investigational use. Commercially available for use in select international markets.
*Until fully deployed.
1. National Institutes of Health. What are congenital heart defects? Retrieved from
2. Dolk, H., Loane, M., Game, E., & European Surveillance of Congenital Anomalies (EUROCAT) Working Group. (2011). Congenital heart defects in Europe: Prevalence and perinatal mortality, 2000 to 2005. Circulation, 123(8), 841-849.
3. Welt, F. G. P., Davidson, M. J., Leon, M. B., & Eisenhauer, A. C. (2011). Transcatheter aortic valve replacement. Circulation, 124, 2944-2948.
4. Forbes, T. (2011, July). Interim results of the Amplatzer septal occluder post approval study. Presented at the meeting of the Pediatric and Adult Interventional Cardiac Symposium, Boston, MA. 
5. Bavaria, J. E., Desai, N. D., Cheung, A., Petracek, M. R., Groh, M. A., Borger, M. A., & Schaff, H. V. (2014). The St. Jude Medical Trifecta aortic pericardial valve: Results from the global, multicenter, prospective clinical study. Journal of Thoracic and Cardiovascular Surgery, 147(2), 590-597.
6. St. Jude Medical. Data on file, Report 90237740.
7. d’Arcy, J. L., Prendergast, B. D., Chambers, J. B., Ray, S. G., & Bridgewater, B. (2011). Valvular heart disease: The next cardiac epidemic. Heart, 97(2), 91-93.
8. Manoharan, G., & Portico, C. E. (2014, September). Trial Assessment of the St. Jude Medical Portico Transcatheter Aortic Valve Implant and the Transfemoral Delivery System. Presented at the meeting of the Transcatheter Cardiovascular Therapeutics, Washington, DC.
9. Everett, A. D., Jennings, J., Sibinga, E., Owada, C., Lim, D. S., Cheatham, J., … Ringel, R. (2009). Community use of the Amplatzer atrial septal defect occluder: Results of the multicenter MAGIC atrial septal defect study. Pediatric Cardiology, 30(3), 240-247.

Orange 24 surrounded by headset, represents "Place an order"

Contact Customer Service

Our customer service experts can help with your product orders or questions.